Trump: Tariffs Driven Novartis to Invest in the US

Meeting Between Trump and Novartis CEO US President Donald Trump met with Novartis CEO Vas Narasimhan at the White House to discuss the company's future operations in the country.
Following the meeting, while addressing workers at a steel plant in Georgia, Trump stated that Narasimhan informed him of the company's decision to build new facilities in the US specifically due to the implemented tariffs.
Company officials noted that the US administration has been provided with comprehensive information regarding these strategic advancements.
$23 Billion Investment Package The Swiss pharmaceutical manufacturer announced a massive $23 billion investment package last year, aimed at constructing 10 new facilities and expanding existing capacity across the United States.
This decision is widely viewed as a strategic response to the Trump administration's threats of imposing customs duties on imported medications.
Drug Prices and Future Plans Novartis and the White House reached a consensus late last year on measures to lower drug prices.
As part of this agreement, the company plans to expand Medicaid discounts and maintain its research and development investments in the US.
These steps are considered part of a broader strategy to solidify the company's long-term presence in the American market.